Boston Scientific: Multi-Year Double-Digit Growth Outlook Makes Share Pullback a Buy Opportunity

Citi analyst Joanne Wuensch reiterated a Buy rating on Boston Scientific yesterday and set a price target of $102.00.

Joanne Wuensch has given his Buy rating due to a combination of factors tied to Boston Scientific’s multi-year growth outlook and refined guidance. She notes that management’s 2026 revenue forecast of 10–11% growth is underpinned by Electrophysiology expanding faster than the roughly 15% market, supported by international PFA uptake, continued OPAL and catheter utilization, and broader adoption of the Farapoint platform.

Moreover, she highlights solid double‑digit expectations across key franchises, including left atrial appendage closure growing around 20% in line with Watchman, and improving trajectories in Vascular Therapies, Urology, and CRM as the year progresses. With revenue and EPS estimates only modestly adjusted and long‑term growth still projected in the low‑teens through 2028, Wuensch sees the recent share pullback as overdone and believes the current setup allows for approximately 34% upside as consensus expectations reset appropriately.

In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $100.00 price target.